Helus Pharma Backs White House Psychedelic Research Push
Event summary
- Helus Pharma supports White House Executive Order accelerating psychedelic research and regulatory pathways for mental health treatments.
- Order includes FDA review prioritization, expanded patient access, and federal funding for state programs.
- Helus Pharma's HLP003 (Phase 3) has FDA Breakthrough Therapy designation for major depressive disorder.
- Company operates in US, Canada, UK, and Ireland with pipeline targeting depression and anxiety disorders.
The big picture
The White House Executive Order signals growing government support for psychedelic therapies, potentially accelerating development timelines and improving patient access. Helus Pharma stands to benefit from this policy shift, particularly with its FDA-designated Breakthrough Therapy in late-stage trials. The broader mental health sector could see increased investment as regulatory barriers lower.
What we're watching
- Regulatory Momentum
- Whether the Executive Order will translate into faster FDA approvals for psychedelic therapies.
- Clinical Validation
- How Helus Pharma's Phase 3 trial for HLP003 progresses under the new regulatory framework.
- Market Expansion
- The pace at which psychedelic treatments gain broader insurance coverage and patient access.